- Home
- TCRX vs ACHV Comparison
TCRX vs ACHV Comparison
Compare TCRX & ACHV Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- TCRX
- ACHV
- Stock Information
- Founded
- TCRX 2018
- ACHV N/A
- Country
- TCRX United States
- ACHV Canada
- Employees
- TCRX N/A
- ACHV N/A
- Industry
- TCRX Biotechnology: Pharmaceutical Preparations
- ACHV Biotechnology: In Vitro & In Vivo Diagnostic Substances
- Sector
- TCRX Health Care
- ACHV Health Care
- Exchange
- TCRX Nasdaq
- ACHV Nasdaq
- Market Cap
- TCRX 98.5M
- ACHV 92.6M
- IPO Year
- TCRX 2021
- ACHV N/A
- Fundamental
- Price
- TCRX $1.38
- ACHV $2.70
- Analyst Decision
- TCRX Strong Buy
- ACHV Strong Buy
- Analyst Count
- TCRX 6
- ACHV 4
- Target Price
- TCRX $9.83
- ACHV $15.75
- AVG Volume (30 Days)
- TCRX 442.7K
- ACHV 162.2K
- Earning Date
- TCRX 03-05-2025
- ACHV 03-11-2025
- Dividend Yield
- TCRX N/A
- ACHV N/A
- EPS Growth
- TCRX N/A
- ACHV N/A
- EPS
- TCRX N/A
- ACHV N/A
- Revenue
- TCRX $2,816,000.00
- ACHV N/A
- Revenue This Year
- TCRX $32.21
- ACHV N/A
- Revenue Next Year
- TCRX $118.35
- ACHV N/A
- P/E Ratio
- TCRX N/A
- ACHV N/A
- Revenue Growth
- TCRX N/A
- ACHV N/A
- 52 Week Low
- TCRX $1.28
- ACHV $2.51
- 52 Week High
- TCRX $9.69
- ACHV $5.59
- Technical
- Relative Strength Index (RSI)
- TCRX 31.10
- ACHV 41.28
- Support Level
- TCRX $1.44
- ACHV $2.70
- Resistance Level
- TCRX $1.76
- ACHV $2.99
- Average True Range (ATR)
- TCRX 0.17
- ACHV 0.20
- MACD
- TCRX -0.01
- ACHV 0.01
- Stochastic Oscillator
- TCRX 16.39
- ACHV 34.55
About TCRX TScan Therapeutics Inc.
TScan Therapeutics Inc is a biopharmaceutical company focused on the development of T-cell receptor (TCR) engineered T cell therapies (TCR-T) for the treatment of patients with cancer. The company's liquid tumor TCR-T therapy candidates, TSC-100 and TSC-101, are in development for the treatment of patients with hematologic malignancies to eliminate residual leukemia and prevent relapse after hematopoietic stem cell transplantation. It is also developing multiplexed TCR-T therapy candidates for the treatment of various solid tumors.
About ACHV Achieve Life Sciences Inc.
Achieve Life Sciences Inc is a specialty pharmaceutical company committed to advancing cytisinicline as a widely available treatment option to help people battling nicotine addiction. It is an established smoking cessation treatment that has been approved and marketed in Central and Eastern Europe. Achieve's focus is to address the smoking health epidemic through the development and commercialization of cytisinicline. It has one operating segment, dedicated to the development and commercialization of cytisinicline for niceon.